8-K - Crinetics Pharmaceuticals, Inc. | StockGist

Current Report Details

Event Type

Financial Results

Regulation Fd

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

Results of Operations and Financial Condition. On January 13, 2026, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) reiterated certain previously

Financial Results

$5.0M

7.01

Regulation FD Disclosure. On January 13, 2026 at 9:45 a.m. Pacific Time, Scott Struthers, Ph.D., Founder and Chief Executive Officer of the Company, presented a

Regulation Fd

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate Slide Presentation 104 Cover Page Interactive Data File (embedded within

Exhibits Only

Source Document

Exhibits (2)

8-K

99.1

EX-99.1